证券代码：688073 证券简称：毕得医药 公告编号：2025-081 减持计划的主要内容 上海毕得医药科技股份有限公司 因股东自身流动性需求，股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿勇、 蒋亚妹计划根据市场情况拟于本减持计划披露之日起3个交易日后的3个月内通 过集中竞价方式减持其所持有的公司股份，减持数量不超过公司总股本的 1.00%。 其中，李怡静减持公司股份数量不超过 227,854 股，即不超过公司总股本的 0.25%； 1 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 截至本公告披露日，上海毕得医药科技股份有限公司（以下简称"毕得医药" 或"公司"）股东李怡静持有公司无限售条件流通股 374,193 股，占公司股份总 数的 0.41%。股东陈俊持有公司无限售条件流通股 224,515 股，占公司股份总数 的 0.25%。股东李黎持有公司无限售条件流通股 224,515 股，占公司股份总数的 0.25%。股东杜鹃持有公司无限售条件流通股 224 ...

每经AI快讯，9月12日，毕得医药(688073.SH)公告称，股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿 勇、蒋亚妹计划根据市场情况拟于本减持计划披露之日起3个交易日后的3个月内通过集中竞价方式减持 其所持有的公司股份，减持数量不超过公司总股本的1.00%。 ...

国泰海通证券股份有限公司 关于上海毕得医药科技股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：毕得医药 | | --- | --- | | 保荐代表人姓名：雷浩、李华东 | 被保荐公司代码：688073.SH | 重大事项提示 经中国证券监督管理委员会《关于同意上海毕得医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]1885 号）批复，上海毕得医药科技 股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股票 1,622.9100 万股，每股面值人民币 1 元，每股发行价格人民币 88.00 元，募集资 金总额为人民币 142,816.08 万元，扣除发行费用后，实际募集资金净额为人民币 130,899.89 万元。本次发行证券已于 2022 年 10 月 11 日在上海证券交易所上市。 国泰海通证券股份有限公司（以下简称"保荐机构"或"国泰海通"）担任其持续督 导保荐机构，持续督导期间为 2022 年 10 月 11 日至 2025 年 12 月 31 日。 在 2025 年 1 月 1 日至 202 ...

截至发稿，曹阳累计任职时间1年364天，现任基金资产总规模1275.43万元，任职期间最佳基金回报 44.37%， 任职期间最差基金回报-33.52%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，上海毕得医药科技股份有限公司位于上海市杨浦区翔殷路999号3幢6层，成立日期2007年4月 27日，上市日期2022年10月11日，公司主营业务涉及聚焦于新药研发产业链前端,依托药物分子砌块的 研发设计、生产及销售等核心业务,能够为新药研发机构提供结构新颖、功能多样的药物分子砌块及科 学试剂等产品。主营业务收入构成为：分子砌块杂环化合物43.26%，分子砌块苯环化合物23.32%，分 子砌块脂肪族类化合物16.36%，催化剂和配体10.57%，生命科学试剂6.49%。 责任编辑：小浪快报 从基金十大重仓股角度 红塔红土医药精选股票发起式A（020331）成立日期2024年4月2日，最新规模1166.63万。今年以来收益 40.01%，同类排名511/4222；近一 ...

Group 1 - Bid Pharma's stock price decreased by 5.26% to 62.38 CNY per share, with a trading volume of 73.24 million CNY and a turnover rate of 2.63%, resulting in a total market capitalization of 5.669 billion CNY [1] - The company focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [1] - The main revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Hongta Hongtu Fund has a significant holding in Bid Pharma, with the Hongta Hongtu Medical Selected Stock Fund A (020331) reducing its position by 157 shares, holding a total of 11,300 shares, which accounts for 5.16% of the fund's net value [2] - The fund has experienced a year-to-date return of 45.4% and a one-year return of 57.15%, ranking 377 out of 4222 and 1498 out of 3798 respectively [2] - The fund manager, Cao Yang, has been in position for 1 year and 363 days, with the fund's total asset size at 12.7543 million CNY and a best return of 44.37% during his tenure [3]

Core Viewpoint - Bid Pharma's stock price has shown a year-to-date increase of 33.56%, but has recently experienced a decline of 4.59% over the past five trading days, indicating volatility in its performance [1]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma achieved an operating income of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, reflecting a year-on-year increase of 41.60% [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Bid Pharma increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Among the top ten circulating shareholders, notable changes include: - China Europe Medical Health Mixed A (003095) as the second-largest shareholder, holding 4.2526 million shares, down by 193,100 shares from the previous period - Agricultural Bank of China Medical Health Stock (000913) as the fourth-largest shareholder, holding 841,000 shares, up by 177,500 shares - New entrants include Guangfa Xinxing Mixed A (002132) and Changxin Jinli Trend Mixed A (519994) [3].

Core Viewpoint - The major shareholders of Shanghai Bid Pharmaceutical Technology Co., Ltd. plan to reduce their holdings due to liquidity needs, with specific details on the number of shares and methods of reduction outlined in the announcement [1][2]. Shareholding Structure - As of the announcement date, major shareholder Zhoushan Xinxie Enterprise Management Partnership holds 5,019,806 shares, accounting for 5.52% of the total shares. Ningbo Landan Enterprise Management Partnership holds 4,305,076 shares, representing 4.74%, with 69,486 shares being subject to restrictions. Shareholder Wu Bo holds 785,804 shares, making up 0.86% of the total shares. Together, these shareholders hold a total of 11.12% of the company [1][2]. Reduction Plan Details - Zhoushan Xinxie plans to reduce up to 908,829 shares (1.00% of total shares) through block trading, while Ningbo Landan also plans to reduce up to 908,829 shares (1.00%). Wu Bo intends to reduce up to 785,804 shares (0.86%) through centralized bidding. The reduction prices will be determined based on market conditions at the time of the sale [2][3]. Shareholder Commitments - The major shareholders have made commitments regarding their shareholding, including a lock-up period of 12 months post-IPO during which they will not transfer or manage their shares. After this period, any reduction within 24 months will be based on market prices and not below the issue price [5][6][8]. Compliance with Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange rules. The shareholders are committed to adhering to these regulations and will disclose their reduction plans three trading days in advance [7][9][13].

Core Viewpoint - The major shareholders of Shanghai Bid Pharmaceutical Technology Co., Ltd. plan to reduce their holdings due to liquidity needs, with specific details on the number of shares and methods of reduction outlined in the announcement [1][2][4]. Shareholder Information - The major shareholder, Zhoushan Xinxie Enterprise Management Partnership (Limited Partnership), holds 5,019,806 shares, accounting for 5.52% of the total shares [1][2]. - Another shareholder, Ningbo Landan Enterprise Management Partnership (Limited Partnership), holds 4,305,076 shares, representing 4.74% of the total shares [3][4]. - The total shares held by Zhoushan Xinxie, Ningbo Landan, and their associated party, Wu Bo, amount to 11.12% of the company [1][4]. Reduction Plan Details - Zhoushan Xinxie plans to reduce up to 908,829 shares, not exceeding 1.00% of the total share capital, through block trading [2][5]. - Ningbo Landan also intends to reduce up to 908,829 shares, with the same percentage limit and method [2][5]. - Wu Bo plans to reduce up to 785,804 shares through centralized bidding, which is 0.86% of the total shares [2][5]. Reduction Timeline - The reduction period is set from September 29, 2025, to December 28, 2025 [5][6]. Shareholding Source - The shares held by Zhoushan Xinxie and Ningbo Landan were acquired before the company's initial public offering (IPO) and through capital reserve conversion [2][4]. - Wu Bo's shares were obtained through a non-trading transfer after the dissolution of the original shareholder, Dinghua Yongchuan Venture Capital Partnership (Limited Partnership) [4][5]. Compliance and Commitments - The major shareholders have made commitments regarding their shareholding, including a lock-up period for shares acquired before the IPO [6][7]. - The shareholders will comply with relevant laws and regulations during the reduction process, ensuring that the actions do not affect the company's governance structure or control [10][11].

Core Viewpoint - Bid Pharma (688073.SH) announced that its shareholders Zhoushan Xinxie, Ningbo Landan, and their concerted action person Mr. Wu Bo plan to reduce their holdings in the company [1] Shareholder Reduction Plans - Zhoushan Xinxie intends to reduce its shareholding by no more than 908,800 shares through block trading, which accounts for no more than 1.00% of the company's total share capital [1] - Ningbo Landan also plans to reduce its shareholding by no more than 908,800 shares through block trading, representing no more than 1.00% of the company's total share capital [1] - Shareholder Wu Bo plans to reduce his shareholding by no more than 785,800 shares through centralized bidding, which is no more than 0.86% of the company's total share capital [1]

Group 1 - Baoti shares: The controlling shareholder has increased its stake by 1.004% [1] - Chengda Pharmaceutical: Qianhai Shengtai plans to reduce its holdings by 7.27% [1] - Huawu Co., Ltd.: Nie Jinghua and others plan to reduce their holdings by no more than 3% within three months [1] Group 2 - Changjiang Materials: The controlling shareholder plans to reduce its holdings by no more than 3% [1] - Weishi Electronics: The controlling shareholder's reduction plan does not exceed 3% [1] - Jialian Technology: A related party plans to reduce its holdings by 2.6166% within three months [1] Group 3 - Funeng Technology: Shareholders plan to reduce their holdings by no more than 2% [1] - Lanfeng Biochemical: Hainan Wenqin reduced its holdings by 2.00% [1] - Koweil: Shareholders Jingkun Investment and Hetu Investment plan to reduce their holdings by no more than 2.34% [1] Group 4 - Huayin Power: Hunan Energy plans to reduce its holdings by 1% [1] - Bid Pharmaceutical: Zhoushan Xinxin plans to reduce its holdings by 1.00% [1] - Guanhao High-tech: Shareholder Yuechuang Investment plans to reduce its holdings by no more than 1% [1] Group 5 - Juxin Technology: Zhuhai Chenyour plans to reduce its holdings by no more than 0.5% [1] - Tianji Shares: Shantou Tianji reduced its holdings by 0.61% [1]